首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >High-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media
【2h】

High-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media

机译:大剂量阿奇霉素与大剂量阿莫西林-克拉维酸盐治疗复发性或持续性急性中耳炎患儿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Infants and young children, especially those in day care, are at risk for recurrent or persistent acute otitis media (AOM). There are no data on oral alternatives to high-dose amoxicillin-clavulanate for treating AOM in these high-risk patients. In this double-blind, double-dummy multicenter clinical trial, we compared a novel, high-dose azithromycin regimen with high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent AOM. Three hundred four children were randomized; 300 received either high-dose azithromycin (20 mg/kg of body weight once a day for 3 days) or high-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days). Tympanocentesis was performed at baseline; clinical response was assessed at day 12 to 16 and day 28 to 32. Two-thirds of patients were aged ≤2 years. A history of recurrent, persistent, or recurrent plus persistent AOM was noted in 67, 18, and 14% of patients, respectively. Pathogens were isolated from 163 of 296 intent-to-treat patients (55%). At day 12 to 16, clinical success rates for azithromycin and amoxicillin-clavulanate were comparable for all patients (86 versus 84%, respectively) and for children aged ≤2 years (85 versus 79%, respectively). At day 28 to 32, clinical success rates for azithromycin were superior to those for amoxicillin-clavulanate for all patients (72 versus 61%, respectively; P = 0.047) and for those aged ≤2 years (68 versus 51%, respectively; P = 0.017). Per-pathogen clinical efficacy against Streptococcus pneumoniae and Haemophilus influenzae was comparable between the two regimens. The rates of treatment-related adverse events for azithromycin and amoxicillin-clavulanate were 32 and 42%, respectively (P = 0.095). Corresponding compliance rates were 99 and 93%, respectively (P = 0.018). These data demonstrate the efficacy and safety of high-dose azithromycin for treating recurrent or persistent AOM.
机译:婴儿和幼儿,特别是日间护理的儿童,有复发或持续性急性中耳炎(AOM)的风险。没有关于高剂量阿莫西林-克拉维酸口服替代品治疗这些高危患者的资料。在这项双盲,双虚拟多中心临床试验中,我们比较了一种新颖的大剂量阿奇霉素方案与大剂量阿莫西林-克拉维酸盐治疗复发或持续性AOM儿童的关系。 304名儿童被随机分配。 300例接受大剂量阿奇霉素(每天20毫克/千克体重,连续3天)或大剂量阿莫西林-克拉维酸(90毫克/千克,每天两次,共10天)。在基线进行鼓膜穿刺术;在第12至16天和第28至32天评估临床反应。三分之二的患者年龄≤2岁。分别在67%,18%和14%的患者中发现了复发,持续或复发加持续性AOM的病史。从296名意向性治疗患者中的163名(55%)中分离出病原体。在第12至16天,所有患者和≤2岁儿童(分别为85和79%)的阿奇霉素和阿莫西林-克拉维酸的临床成功率均相当(分别为86%和84%)。在第28天至第32天,所有患者和≤2岁患者的阿奇霉素的临床成功率均优于阿莫西林-克拉维酸的临床成功率(分别为72和61%; P = 0.047)和P(分别为68和51%); = 0.017)。在两种方案之间,针对每种病原体的抗肺炎链球菌和流感嗜血杆菌的临床疗效均相当。阿奇霉素和阿莫西林-克拉维酸的治疗相关不良事件发生率分别为32%和42%(P = 0.095)。相应的依从率分别为99%和93%(P = 0.018)。这些数据证明了大剂量阿奇霉素治疗复发或持续性AOM的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号